3-Ethylcyclobutane-1-carbaldehyde | 1784060-14-5

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机氧化物
• 英文名称: 3-Ethylcyclobutane-1-carbaldehyde
• CAS: 1784060-14-5
• 化学式: C₇H₁₂O
• 分子量: 112.17
• InChiKey: AFRINSHOBQKVMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• OIL GELATOR
  申请人：NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITY

  公开号：US20180362454A1

  公开（公告）日：2018-12-20

  There is provided a novel gelator containing a monourea derivative. A gelator comprising a compound of formula (1): wherein R 1 is a linear or branched alkyl group having a carbon atom number of 2 to 20, a cyclic alkyl group having a carbon atom number of 3 to 20, or a linear or branched alkenyl group having a carbon atom number of 12 to 20; and Ar is a C 6-18 aryl group unsubstituted or optionally substituted with at least one substituent selected from the group consisting of a C 1-10 alkyl group, a C 1-10 alkoxy group, a C 6-18 aryloxy group, a halogen atom, a nitro group, a phenyl group, a C 2-10 alkylcarbonyl group, and a C 7-18 aralkyl group.

  提供了一种含有单脲衍生物的新型凝胶剂。一种包含化合物的凝胶剂，其化学式为(1)：其中R1为具有2至20个碳原子数的线性或支链烷基基团，具有3至20个碳原子数的环烷基基团，或具有12至20个碳原子数的线性或支链烯基基团；Ar为未取代或可选择地取代至少一种取代基的C6-18芳基基团，所述取代基选自C1-10烷基基团、C1-10烷氧基基团、C6-18芳氧基基团、卤原子、硝基基团、苯基、C2-10烷基羰基基团和C7-18芳基烷基基团。
• NOVEL HYDROGELATOR
  申请人：NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITY

  公开号：US20190241598A1

  公开（公告）日：2019-08-08

  A novel hydrogelator that contains a monourea compound having a sugar structure, which can be produced by a simple method, includes a compound of the following Formula [1]: (wherein S g is a sugar group, A is a divalent linking group, and R is a linear or branched alkyl group having a carbon atom number of 1 to 15, a cyclic alkyl group having a carbon atom number of 3 to 15, a linear or branched alkenyl group having a carbon atom number of 2 to 15, or a C 6-18 aryl group unsubstituted or substituted with at least one substituent selected from the group consisting of a C 1-10 alkyl group, a C 1-10 alkoxy group, a C 6-18 aryloxy group, a halogen atom, a nitro group, a phenyl group, a C 2-10 alkylcarbonyl group, and a C 7-18 aralkyl group).

  一种新型水凝胶剂，包含具有糖结构的单脲化合物，可以通过简单的方法制备，包括以下式[1]的化合物：（其中S是糖基，A是二价连接基团，R是线性或支链烷基，碳原子数为1至15，环状烷基，碳原子数为3至15，线性或支链烯基，碳原子数为2至15，或未取代或取代至少一个取代基的C6-18芳基，所述取代基选择自C1-10烷基，C1-10烷氧基，C6-18芳氧基，卤素原子，硝基，苯基，C2-10烷基羰基和C7-18芳基烷基组成）。
• Substituted Purine And 7-Deazapurine Compounds
  申请人：Olhava Edward J.

  公开号：US20120142625A1

  公开（公告）日：2012-06-07

  The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及取代嘌呤和7-脱氮嘌呤化合物。本发明还涉及包含这些化合物的药物组合物，以及通过向需要这些化合物和药物组合物的受试者施用这些化合物和药物组合物来治疗DOT1介导的蛋白质甲基化参与的疾病，例如癌症和神经系统疾病的方法。
• Substituted Purine and 7-Deazapurine Compounds
  申请人：Epizyme, Inc.

  公开号：US20140051654A1

  公开（公告）日：2014-02-20

  The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及取代嘌呤和7-去氮嘌呤化合物。本发明还涉及含有这些化合物的药物组合物以及通过向需要这些化合物和药物组合物的受试者施用这些化合物和药物组合物来治疗DOT1介导的蛋白质甲基化参与的疾病，例如癌症和神经系统疾病的方法。
• SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS
  申请人：EPIZYME, INC.

  公开号：US20150366893A1

  公开（公告）日：2015-12-24

  The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及取代嘌呤和7-脱氮嘌呤化合物。本发明还涉及含有这些化合物的制药组合物以及通过向需要这些化合物和制药组合物的受试者施用这些化合物和制药组合物来治疗DOT1介导的蛋白质甲基化参与的疾病，例如癌症和神经系统疾病的方法。